revascularization

(redirected from Arterial revascularization)
Also found in: Dictionary.

revascularization

 [re-vas″ku-lah-rĭ-za´shun]
1. the restoration of blood supply, as after a wound.
2. the restoration of an adequate blood supply to a part by means of a blood vessel graft, as in aortocoronary bypass.

re·vas·cu·lar·i·za·tion

(rē-vas'kyū-lăr-i-zā'shŭn),
Reestablishment of blood supply to a part.

revascularization

/re·vas·cu·lar·iza·tion/ (re-vas´ku-lar-ĭ-za´shun)
1. the restoration of blood supply, as after a wound.
2. the restoration of an adequate blood supply to a part by means of a blood vessel graft, as in aortocoronary bypass.

revascularization

[rēvas′kyəler′īzā′shən]
Etymology: L, re + vasculum, small vessel; Gk, izein, to cause
the restoration by surgical means of blood flow to an organ or a tissue, as in bypass surgery.

revascularization

Vascular disease A surgical procedure in which compromised or stenosed blood vessels are bypassed to treat ischemia; revascularization is the treatment of choice for Pts subsequently found to have abnormal ventricular function and extensive CAD. See CABG.

re·vas·cu·lar·i·za·tion

(rē-vas'kyū-lăr-ī-zā'shŭn)
Reestablishment of blood supply to a part.

revascularization

restoration of blood supply

re·vas·cu·lar·i·za·tion

(rē-vas'kyū-lăr-ī-zā'shŭn)
Reestablishment of blood supply to a body part.

revascularization

the restoration of an adequate blood supply to a part by means of a blood vessel graft, as in aortocoronary bypass.
References in periodicals archive ?
With increases expected in the aging patient population and in incidences of diabetes and obesity, the Society of Interventional Radiology offers its Lower Extremity Arterial RevascularizatioN (LEARN) meeting, Oct.
As a composite or "Y" graft, the RIMA is anastomosed proximally to LIMA, allowing total arterial revascularization instead of using a venous graft with LIMA.
The Arterial Revascularization Therapy Study, reported in abstract form by Dr.
The case group consisted of 144 subjects who developed claudication or underwent peripheral arterial revascularization within 60 months after collection of baseline blood samples, whereas the control group consisted of 144 age- and smoking habit-matched subjects who remained free of vascular disease during the same period as reported previously.
The findings from the Arterial Revascularization Therapy Study (ARTS) I and II were presented today at the annual Transcatheter Cardiovascular Therapeutics (TCT 2005) Conference.
Part B Percutaneous Coronary Intervention, 000 35 Adjunctive techniques for PCi, 000 36 PCi for acute myocardial infarction, 000 37 PCi for complex coronary lesions (left main stem, ostial and bifurcation lesions), 000 38 PCi in multivessel disease, 000 39 PCi for chronic total occlusions, 000 40 PCi for saphenous vein grafts, 000 41 Adjunctive pharmacotherapy for PCi, 000 42 Magnetic catheter navigation for PCi, 000 43 Full arterial revascularization for the treatment of CAd, 000 44 Cell therapy for acute myocardial infarctions, 000
The primary outcome was a composite CVD endpoint, defined as first myocardial infarction (heart attack), stroke, hospitalization for unstable angina (chest pain), arterial revascularization (surgical restoration of blood flow), or cardiovascular death.
In addition to its other approved indications, rosuvastatin (Crestor, AstraZeneca) can now be used for primary prevention in reducing the risk of MI, stroke, and arterial revascularization procedures.
Thirty-eight years-old young patient in this series had LAD and diagonal coronary artery lesions and full arterial revascularization was planned.
The Arterial Revascularization Therapy Study II (ARTS II) study, sponsored by Cordis Corporation, a Johnson & Johnson company, is an extension of ARTS I, which compared results of bare metal stents to those obtained with bypass surgery.
The Company's lead product, the Lifeline(TM) small diameter blood vessel, is the first lab-grown vessel to be used in adult humans for arterial revascularization.
8 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved CRESTOR (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction (heart attack) and arterial revascularization procedures in individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men greater than or equal to 50 and women greater than or equal to 60), high-sensitivity C-reactive protein (hsCRP) greater than or equal to 2 mg/L, and the presence of at least one additional CVD risk factor, such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease.

Full browser ?